FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387308037> ?p ?o ?g. }

• W4387308037 abstract "Background The ORAL Surveillance trial showed a potentially higher incidence of malignancy and major adverse cardiovascular events (MACEs) associated with tofacitinib than those associated with tumor necrosis factor (TNF) inhibitors (TNFis). However, few studies have compared the safety of non-TNFis or other Janus kinase (JAK) inhibitors (JAKis). This study was aimed at comparing the incidence rates (IRs) of malignancies and MACEs in patients with rheumatoid arthritis (RA) treated using interleukin-6 (IL-6) inhibitors (IL-6is) or JAKis. Methods We retrospectively analyzed 427 patients with RA who were treated using an IL-6i (n = 273) or a JAKi (n = 154). We determined the IRs of malignancy and MACEs, and the standardized incidence ratio (SIR) of malignancies and investigated factors related to malignancy and MACEs. After adjusting the clinical characteristic imbalance by propensity score matching (PSM), we compared the IRs of adverse events between the JAKi and IL-6i groups. Results After PSM, the observational period was determined to be 605.27 patient-years (PY), and the median observational period was determined to be 2.28 years. We identified seven cases of malignancy (IR: 2.94 per 100 PY) in the JAKi-treated group and five cases (IR: 1.36 per 100 PY) in the IL-6i-treated group after PSM. The IR of MACEs was 2.56 and 0.83 (per 100 PY) in the JAKi- and IL-6i-treated groups. The IRRs of JAKi-treated patients versus IL-6i-treated patients were 2.13 (95% confidence interval (CI): 0.67–7.42) for malignancy and 3.03 (95% CI: 0.77–15.21) for MACE. There were no significant differences in IRR for malignancy and MACE between both groups after PSM. Univariate and multivariable Cox regression analyses revealed that older age and JAKi use were independent risk factors for malignancy, while older age, hypertension, and JAKi use were independent risk factors for MACEs. The overall malignancy SIR was significantly higher in the JAKi-treated group compared to the general population (2.10/100 PY, 95% CI: 1.23–2.97). Conclusion The IRs of malignancy and MACE in patients with RA after PSM were comparable between IL-6i-treated and JAKi-treated patients. However, the SIR of malignancy in JAKi treatment was significantly higher than in the general population; therefore, further safety studies comparing JAKi to non-TNFi biologic disease-modifying antirheumatic drugs (bDMARDs) are needed." @default.
• W4387308037 created "2023-10-04" @default.
• W4387308037 creator A5000647160 @default.
• W4387308037 creator A5010988080 @default.
• W4387308037 creator A5013815950 @default.
• W4387308037 creator A5020066400 @default.
• W4387308037 creator A5035137329 @default.
• W4387308037 creator A5035151491 @default.
• W4387308037 creator A5038413661 @default.
• W4387308037 creator A5044267497 @default.
• W4387308037 creator A5057574490 @default.
• W4387308037 creator A5059480693 @default.
• W4387308037 creator A5079822291 @default.
• W4387308037 creator A5088939006 @default.
• W4387308037 creator A5091064461 @default.
• W4387308037 date "2023-10-02" @default.
• W4387308037 modified "2023-10-05" @default.
• W4387308037 title "Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study" @default.
• W4387308037 cites W1911773670 @default.
• W4387308037 cites W2019832147 @default.
• W4387308037 cites W2093220748 @default.
• W4387308037 cites W2117335168 @default.
• W4387308037 cites W2128952811 @default.
• W4387308037 cites W2593565645 @default.
• W4387308037 cites W2601742683 @default.
• W4387308037 cites W2903436036 @default.
• W4387308037 cites W2908728730 @default.
• W4387308037 cites W2908878119 @default.
• W4387308037 cites W2922089356 @default.
• W4387308037 cites W3094882380 @default.
• W4387308037 cites W3126579487 @default.
• W4387308037 cites W4205998736 @default.
• W4387308037 cites W4210529991 @default.
• W4387308037 cites W4211054359 @default.
• W4387308037 cites W4211111012 @default.
• W4387308037 cites W4212908502 @default.
• W4387308037 cites W4221009615 @default.
• W4387308037 cites W4282934382 @default.
• W4387308037 cites W4296696831 @default.
• W4387308037 cites W4298005442 @default.
• W4387308037 cites W4311621329 @default.
• W4387308037 cites W4363676888 @default.
• W4387308037 cites W4379600442 @default.
• W4387308037 doi "https://doi.org/10.3389/fimmu.2023.1267749" @default.
• W4387308037 hasPublicationYear "2023" @default.
• W4387308037 type Work @default.
• W4387308037 citedByCount "0" @default.
• W4387308037 crossrefType "journal-article" @default.
• W4387308037 hasAuthorship W4387308037A5000647160 @default.
• W4387308037 hasAuthorship W4387308037A5010988080 @default.
• W4387308037 hasAuthorship W4387308037A5013815950 @default.
• W4387308037 hasAuthorship W4387308037A5020066400 @default.
• W4387308037 hasAuthorship W4387308037A5035137329 @default.
• W4387308037 hasAuthorship W4387308037A5035151491 @default.
• W4387308037 hasAuthorship W4387308037A5038413661 @default.
• W4387308037 hasAuthorship W4387308037A5044267497 @default.
• W4387308037 hasAuthorship W4387308037A5057574490 @default.
• W4387308037 hasAuthorship W4387308037A5059480693 @default.
• W4387308037 hasAuthorship W4387308037A5079822291 @default.
• W4387308037 hasAuthorship W4387308037A5088939006 @default.
• W4387308037 hasAuthorship W4387308037A5091064461 @default.
• W4387308037 hasBestOaLocation W43873080371 @default.
• W4387308037 hasConcept C120665830 @default.
• W4387308037 hasConcept C121332964 @default.
• W4387308037 hasConcept C126322002 @default.
• W4387308037 hasConcept C143998085 @default.
• W4387308037 hasConcept C17923572 @default.
• W4387308037 hasConcept C197934379 @default.
• W4387308037 hasConcept C2776233030 @default.
• W4387308037 hasConcept C2777575956 @default.
• W4387308037 hasConcept C2778886723 @default.
• W4387308037 hasConcept C2779399171 @default.
• W4387308037 hasConcept C61511704 @default.
• W4387308037 hasConcept C71924100 @default.
• W4387308037 hasConcept C90924648 @default.
• W4387308037 hasConceptScore W4387308037C120665830 @default.
• W4387308037 hasConceptScore W4387308037C121332964 @default.
• W4387308037 hasConceptScore W4387308037C126322002 @default.
• W4387308037 hasConceptScore W4387308037C143998085 @default.
• W4387308037 hasConceptScore W4387308037C17923572 @default.
• W4387308037 hasConceptScore W4387308037C197934379 @default.
• W4387308037 hasConceptScore W4387308037C2776233030 @default.
• W4387308037 hasConceptScore W4387308037C2777575956 @default.
• W4387308037 hasConceptScore W4387308037C2778886723 @default.
• W4387308037 hasConceptScore W4387308037C2779399171 @default.
• W4387308037 hasConceptScore W4387308037C61511704 @default.
• W4387308037 hasConceptScore W4387308037C71924100 @default.
• W4387308037 hasConceptScore W4387308037C90924648 @default.
• W4387308037 hasLocation W43873080371 @default.
• W4387308037 hasOpenAccess W4387308037 @default.
• W4387308037 hasPrimaryLocation W43873080371 @default.
• W4387308037 hasRelatedWork W2014330392 @default.
• W4387308037 hasRelatedWork W2052064556 @default.
• W4387308037 hasRelatedWork W2132809463 @default.
• W4387308037 hasRelatedWork W2755978387 @default.
• W4387308037 hasRelatedWork W2916556513 @default.
• W4387308037 hasRelatedWork W2939528202 @default.
• W4387308037 hasRelatedWork W2972486011 @default.
• W4387308037 hasRelatedWork W3085086630 @default.
• W4387308037 hasRelatedWork W4226373090 @default.

• next